Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Surgery Partners (SGRY) EPS (Weighted Average and Diluted) (2016 - 2025)

Surgery Partners' EPS (Weighted Average and Diluted) history spans 12 years, with the latest figure at -$0.11 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 87.21% year-over-year to -$0.11; the TTM value through Dec 2025 reached -$0.61, up 54.14%, while the annual FY2025 figure was -$0.61, 54.14% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.11 at Surgery Partners, up from -$0.18 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.37 in Q4 2023 and bottomed at -$0.86 in Q4 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.19 (2023), against an average of -$0.17.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 254.91% in 2023 before it plummeted 525.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.12 in 2021, then crashed by 300.0% to -$0.24 in 2022, then soared by 254.91% to $0.37 in 2023, then plummeted by 331.32% to -$0.86 in 2024, then surged by 87.21% to -$0.11 in 2025.
  • Per Business Quant, the three most recent readings for SGRY's EPS (Weighted Average and Diluted) are -$0.11 (Q4 2025), -$0.18 (Q3 2025), and -$0.02 (Q2 2025).